Alli hits European stores
This article was originally published in The Tan Sheet
Pharmacies across Europe now sell GlaxoSmithKline's non-prescription weight-loss drug alli (orlistat 60 mg), the firm says April 20. The European Commission, in its first centralized Rx-to-OTC switch process, approved the product for non-Rx sale to adults with a body mass index of 28 kg/m2 or more in all 27 EU member countries (1"The Tan Sheet" Jan. 26, 2009, In Brief)
You may also be interested in...
Brand innovation, continued investment in marketing and global expansion help drive up GlaxoSmithKline's consumer health care sales significantly faster than overall market growth, the firm says
The European Union approves GlaxoSmithKline's weight-loss drug alli (orlistat 60 mg) for nonprescription sale in all 27 member states and Norway. The company says Jan. 21 it plans to launch alli - the first centralized EU switch - in the coming months. While all EU members agree to sell alli as nonprescription, each country chooses whether to make it available over the counter or behind the counter, the European Medicines Agency says (1"The Tan Sheet" Nov. 17, 2008, p. 6)
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.